ABBVAbbVieSigning up patients
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
Solid Tumors Harboring MET Amplification
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 100 (planned)
- Started
- Dec 1, 2025
- Main results expected
- Dec 2030
- Fully finished
- Dec 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants with Adverse Events (AE)s
Measured over: Up to 61.5 Months
Confirmed Objective Response (OR) as Assessed by Independent Central Review (ICR)
Measured over: Up to 36 Months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07196644 · record last updated 2026-08-14 · checked 2026-11-09 15:47 UTC